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938Prevalence and Impact of Atrial Fibrillation in
Patients With Severe Aortic Stenosis Undergoing
Transcatheter Aortic Valve Replacement
An Analysis From the SOURCE XT Prospective
Multicenter RegistryABSTRACTOBJECTIVES The aims of this study were to assess the epidemiology of atrial ﬁbrillation (AF) in patients treated with
transcatheter aortic valve replacement (TAVR) and included in the large prospective SOURCE XT (SAPIEN XT Aortic
Bioprosthesis Multi-Region Outcome Registry) study and to evaluate their outcomes according to the presence of
pre-existing or new-onset AF (NOAF) (deﬁned as AF occurring within 30 days after TAVR).
BACKGROUND Data on the epidemiology and clinical impact of AF in patients undergoing TAVR are scant and limited
to small retrospective studies.
METHODS The SOURCE XT study is a multicenter, prospective registry of consecutive patients treated with the SAPIEN
XT valve at 99 sites in 17 countries. Follow-up was scheduled at discharge, 1 month, 1 year, and yearly thereafter. Patients
(n ¼ 2,706) were categorized according to the presence of pre-existing or NOAF.
RESULTS The prevalence of pre-existing AF was 35.6%, whereas NOAF occurred in 7.2% of patients. Both pre-existing
AF and NOAF correlated with worse clinical outcomes compared with patients in sinus rhythm, including all-cause death,
cardiac death, and bleeding events. NOAF was associated with higher rates of stroke at 2 years compared with sinus
rhythm. Independent predictors of NOAF were age (hazard ratio: 1.1), New York Heart Association class III or IV (hazard
ratio: 1.9), nontransfemoral access route (hazard ratio: 3), and balloon post-dilation (odds ratio: 1.6). No interaction was
observed between any degree of post-implantation paravalvular leak and NOAF.
CONCLUSIONS In the large dataset of the SOURCE XT registry, the presence of either pre-existing or NOAF increased
all-cause and cardiac mortality and bleeding events. NOAF was associated with increased stroke rates at long-term
follow-up. (J Am Coll Cardiol Intv 2016;9:937–46) © 2016 by the American College of Cardiology Foundation.T ranscatheter aortic valve replacement (TAVR)is an established treatment for patients withaortic valve stenosis who are inoperable or
at high risk for surgery (1,2). A substantial proportion
of patients who are scheduled for TAVR are diagnosed
with paroxysmal or permanent atrial ﬁbrillation (AF)
at the time of the screening for eligibility for TAVR
(3). Moreover, new-onset AF (NOAF) is a frequent
ﬁnding in the post-operative period after TAVR proce-
dures (4). AF is a well-established predictor of adverse
outcomes in patients with aortic stenosis, and several
previous studies demonstrated increased risk for mor-
tality related to AF in patients undergoing open-chest
valve surgery (5–7). However, data on the prevalenceSEE PAGE 947and impact of pre-existing AF or NOAF in the setting
of TAVR are scant and limited to small retrospectivestudies that have speciﬁcally focused on this issue
(8–11). In the present study, we sought to evaluate
the epidemiology, predictors, and prognostic implica-
tions of AF, either pre-existing or new onset, in TAVR
patients using the large dataset of the SOURCE XT
(SAPIEN XT Aortic Bioprosthesis Multi-Region
Outcome Registry) prospective registry (12).
METHODS
REGISTRY. The SOURCE XT study (NCT01238497) is a
multination, multicenter, prospective, observational
registry of consecutively enrolled patients. Data on all
patients consecutively treated with the commercially
available SAPIEN XT valve (Edwards Lifesciences,
Irvine, California) at 99 sites in 17 countries were used
for this analysis. Patients treated with other valves
were not included. One site, which enrolled 6 pa-
tients, was excluded for noncompliance with
AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
HR = hazard ratio
NOAF = new-onset atrial
ﬁbrillation
TAVR = transcatheter aortic
valve replacement
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 9 , 2 0 1 6 Tarantini et al.
M A Y 9 , 2 0 1 6 : 9 3 7 – 4 6 Prevalence and Impact of Atrial Fibrillation in TAVR Patients
939regulatory requirements. Additionally, 9 patients
from other participating sites were excluded for not
providing informed consent forms. From a total of
2,706 consented patients enrolled between July 2010
and November 2011, no procedure was attempted in
18 patients. Therefore, 2,688 patients remained in the
ﬁnal cohort and were included in this analysis.
Patient data were collected at discharge, 30 days,
12 months, and 24 months post-implantation. This
study complied with the Declaration of Helsinki, and
the local regulatory authorities approved the research
protocol at each site. Informed consent was obtained
from all subjects (or their guardians).
DEVICES AND PROCEDURE. The SAPIEN XT valve is
composed of a nickel-cobalt chromium stent frame, a
trileaﬂet bovine pericardial tissue valve, and a
polyethylene-terephthalate fabric skirt. The valve
was available in 23- and 26-mm sizes for all delivery
approaches. The 29-mm valve size was available for
the transapical approach only. The NovaFlex delivery
system, which includes an integrated distal tip and
has a low-crossing proﬁle, was used for the trans-
femoral approach with 18-F (23-mm valve) or 19-F
(26-mm valve) introducer sheaths. The Ascendra
delivery system was used for transapical access.
PATIENT SELECTION. High-surgical-risk patients
with severe symptomatic aortic stenosis were deemed
eligible for the procedure. Logistic European System
for Cardiac Operative Risk Evaluation score was used
as a general tool for surgical risk assessment. However,
the local heart team, considering all underlying con-
ditions, made the ﬁnal decision. Examinations were
based on standards of care for TAVR at each partici-
pating site. Annular diameter was measured by
computed tomography and/or transthoracic and/or
transesophageal echocardiography; however, only
transthoracic echocardiographic data were required.
DATA COLLECTION. All data were entered in the
electronic data capturing system and monitored. An
independent clinical events committee adjudicated
all adverse events, according to the Valve Academic
Research Consortium criteria (13).
STUDY DEFINITIONS. NOAF was deﬁned as any
episode of AF occurring within 30 days after TAVR in
a patient with no previous known AF, lasting long
enough to be recorded on a 12-lead electrocardio-
gram or at least 30 s on a rhythm strip (8,14,15). All
study endpoints were deﬁned according to Valve
Academic Research Consortium deﬁnitions (13). The
main outcome measures in the SOURCE XT registry
were all-cause death, cardiac death, and stroke.
Secondary measures included major vascular com-
plications, major and life-threatening bleedingepisodes, acute kidney injury, permanent
pacemaker insertion, procedural and device-
related complications, functional status, and
echocardiographic assessment of valve and
heart function. No echocardiography core
laboratory was used. Therefore, all echo-
cardiographic data were site reported.
Procedural success was deﬁned as 1 valve
implanted at the intended site in 1 attempted
procedure without procedure-related death within
48 h of implantation. Device success was deﬁned
further as a successfully delivered valve with a ﬁnal
gradient #20 mm Hg and no moderate or severe
aortic regurgitation at discharge.
STATISTICAL ANALYSES. Continuous variables are
presented as mean  SD, and comparisons were made
with 2-sample Student t tests. Categorical data are
presented as percentages, and comparisons between
groups were done using Fisher exact tests or chi-
square tests. Paired Student t tests and McNemar
tests were used to perform paired comparisons of
continuous and categorical variables. The log-rank
test was used to compare survival curves for time-to-
event variables, which were constructed with the use
of Kaplan-Meier estimates. An analysis was made to
consider a site effect in the all-causemortality analysis
by use of the Wei-Lin-Weissfeld model. Predictors
of adverse outcomes and of AF were determined
using univariate Cox proportional hazards regression
with baseline variables and NOAF as covariates. A
multivariate model with a stepwise procedure was
then used to test all independent predictors with p
values <0.10. The Cox proportional hazards assump-
tion of the ﬁnal mortality model was tested using the
Wei-Lin-Yang method. Analyses were performed with
SAS version 9.3 (SAS Institute, Cary, North Carolina).
RESULTS
Among 2,706 consecutive patients with aortic steno-
sis enrolled in the SOURCE XT registry (Figure 1),
2,688 patients underwent TAVR via transfemoral
(n ¼ 1,685 [62.7%]), transapical (n ¼ 894 [33.3%]),
direct transaortic (n ¼ 101 [3.8%]), or trans-subclavian
(n ¼ 8 [0.3%]) access routes. Follow-up was complete
in 99% of patients at 1 year and in 86% at 2 years.
Among 1,925 patients with complete heart rhythm
data at baseline and follow-up, the observed preva-
lence of pre-existing AF (either paroxysmal or per-
manent) was 35.6%. A signiﬁcantly higher prevalence
of pre-existing AF was observed in patients treated
using the transapical approach compared with those
treated using the transfemoral approach (41.8% and
32.7%, respectively; p < 0.01). NOAF was observed in
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9407.2% of patients following TAVR. For subsequent
analyses, 3 study groups were considered: patients
in sinus rhythm up to 30 days after TAVR and
without any history of AF (n ¼ 1,102), patients with
pre-existing AF (n ¼ 685), and patients with NOAF
(n ¼ 138). The baseline characteristics and procedural
data of these groups are shown in Tables 1 and 2.
Notably, patients with pre-existing AF had the high-
est surgical risk compared with the other groups.
Related to procedural characteristics, the NOAF group
had higher rates of transapical access, use of the
largest prosthetic valve size (29 mm, available for the
transapical access only), general anesthesia, balloon
pre- or post-dilation, technical success, and device
success compared with both other study groups.
The event-free survival curves at 1 year of patients
treated by TAVR according to the presence of AF are
shown in Figure 2. Overall, patients with AF (either
pre-existing or new onset) had worse outcomes
compared with those in sinus rhythm in terms of all-
cause mortality and of the combination of all-cause
mortality and stroke. These results were not affected
by site variability. Among patients with AF, NOAF
trended toward an association with increased all-
cause mortality and combined all-cause mortality
and stroke compared with the pre-existing AF group.FIGURE 1 Flow of Patients in the SAPIEN XT Aortic Bioprosthesis M
Among 2,706 patients (Pts) enrolled between July 2010 and October 2
replacement (TAVR) and 33.3% underwent transapical TAVR. Of the total
and 85.8% at 2 years. *4 patients who missed the 30-day visit were asTable 3 reports combined and single adverse event
rates at 1 year for each study group. Higher rates of
both all-cause mortality and cardiac death were
observed in patients with AF compared with the sinus
rhythm group. Also, a numerically higher rate of all-
cause and cardiac mortality was observed in the
NOAF group compared with the pre-existing AF group.
Overall, patients with AF showed also higher rates
of bleeding, renal impairment, and rehospitalization
compared with those in sinus rhythm. Patients with
NOAF had a higher incidence of bleeding and renal
impairment compared with the pre-existing AF
group. Cerebrovascular event rates did not differ
among groups. Among 194 adjudicated strokes, 51.0%
(n ¼ 99) occurred more than 30 days after TAVR. The
time course of stroke events after the index proce-
dure is shown in the Online Appendix.
Consistent with 1-year results, at 2-year follow-up,
patients with AF had worse outcomes compared with
the sinus rhythm group in terms of all-cause and
cardiac mortality, bleeding (both major and minor),
and rehospitalization. Outcomes and event-free sur-
vival curves at 2-year follow-up are detailed in the
Online Appendix. At 2 years, only the NOAF group
showed a signiﬁcantly higher stroke rate compared
with the sinus rhythm group (6.6% vs. 11.8%,ulti-Region Outcome Registry
011, 62.7% underwent transfemoral transcatheter aortic valve
cohort, 98.7% of patients had study follow-up (FU) available at 1 year
sessed at the 1-year follow-up.
TABLE 1 Baseline Characteristics According to the Presence of Pre-Existing or
New-Onset Atrial Fibrillation
Pre-Existing AF
(n ¼ 685)
NOAF
(n ¼ 138)
Sinus Rhythm
(n ¼ 1,102) p Value
Age (yrs) 81.6  5.8 82.8  6.0 81.0  6.5 0.002
Women 387 (56.5%) 79 (57.2%) 664 (60.3%) 0.27
BMI (kg/m2) 26.7  5.0 27.0  5.2 26.7  4.8 0.78
Logistic EuroSCORE (%) 22.4  13.4 21.6  12.4 18.9  11.3 <0.0001
STS score 8.5  6.7 7.6  5.1 7.3  6.0 0.001
NYHA functional class 0.16
I/II 134 (19.6%) 23 (16.9%) 259 (23.6%)
III/IV 550 (80.4%) 113 (83.1%) 838 (76.4%)
History of syncope 83 (12.1%) 18 (13.0%) 161 (14.6%) 0.31
History of angina (CCS 1–4) 316 (46.7%) 55 (40.1%) 475 (43.5%) 0.34
Congestive heart failure 480 (70.1%) 83 (60.1%) 631 (57.3%) <0.0001
Myocardial infarction 104 (15.2%) 23 (16.7%) 152 (13.8%) 0.54
Hyperlipidemia/hypercholesterolemia 334 (48.8%) 77 (55.8%) 653 (59.3%) <0.0001
Hypertension 550 (80.3%) 121 (87.7%) 904 (82.0%) 0.12
Smoker (current or previous) 168 (24.6%) 36 (26.1%) 259 (23.5%) 0.74
Previous pacemaker/ICD 102 (14.9%) 24 (17.4%) 50 (4.5%) <0.0001
Peripheral vascular disease 151 (22.1%) 29 (21.0%) 224 (20.3%) 0.67
Porcelain aorta 38 (5.6%) 4 (2.9%) 75 (6.8%) 0.16
Endocarditis 11 (1.6%) 1 (0.7%) 11 (1.0%) 0.45
Diabetes 219 (32.0%) 37 (26.8%) 289 (26.2%) 0.02
Stroke 71 (10.4%) 12 (8.7%) 83 (7.5%) 0.11
TIA 29 (4.2%) 9 (6.5%) 46 (4.2%) 0.44
Previous PCI 198 (28.9%) 45 (32.6%) 332 (30.1%) 0.65
Previous CABG 106 (15.5%) 18 (13.0%) 164 (14.9%) 0.76
Previous peripheral vascular
intervention
17 (2.5%) 3 (2.2%) 19 (1.7%) 0.53
Previous thoracic aorta surgery 5 (0.7%) 0 (0.0%) 2 (0.2%) 0.24
Aortic regurgitation (moderate/severe) 111 (17.3%) 27 (20.3%) 160 (15.4%) 0.27
Mitral regurgitation (moderate/severe) 184 (27.3%) 30 (21.9%) 188 (17.4%) <0.0001
Pulmonary hypertension 230 (33.6%) 33 (23.9%) 218 (19.8%) <0.0001
COPD 156 (22.8%) 28 (20.3%) 221 (20.1%) 0.37
CNS disorder 14 (2.0%) 4 (2.9%) 45 (4.1%) 0.07
Dementia 10 (1.5%) 6 (4.3%) 20 (1.8%) 0.08
Severe renal impairment
(eGFR <30 ml/min) or dialysis
214 (31.3%) 47 (34.1%) 257 (23.3%) 0.0002
Severe liver disease 18 (2.6%) 1 (0.7%) 37 (3.4%) 0.23
Chest deformities 4 (0.6%) 1 (0.7%) 12 (1.1%) 0.54
Malignancy 109 (15.9%) 25 (18.1%) 193 (17.5%) 0.63
AV block (any) 24 (3.5%) 23 (16.8%) 150 (13.6%) <0.0001
Left bundle branch block (complete) 46/685 (6.7%) 9/138 (6.5%) 102 (9.3%) 0.12
Right bundle branch block (complete) 58/685 (8.5%) 8/138 (5.8%) 58 (5.3%) 0.02
Values are mean  SD, n (%), or n/N (%).
AF ¼ atrial ﬁbrillation; AV ¼ atrioventricular; BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting;
CCS ¼ Canadian Cardiovascular Society; CNS ¼ central nervous system; COPD ¼ chronic obstructive pulmonary
disease; eGFR ¼ estimated glomerular ﬁltration rate; EuroSCORE ¼ European System for Cardiac Operative Risk
Evaluation; ICD ¼ implantable cardioverter-deﬁbrillator; NOAF ¼ new-onset atrial ﬁbrillation; NYHA ¼ New York
Heart Association; PCI¼ percutaneous coronary intervention; STS¼ Society of Thoracic Surgeons; TIA¼ transient
ischemic attack.
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941p ¼ 0.02). A detailed description of all cerebrovascu-
lar events at all follow-up intervals is provided in the
Online Appendix. Of note, 90.6% of surviving
patients in the NOAF group (n ¼ 125) were found to
have AF at 30-day follow-up, while this rate increased
to 100% both at 1-year and 2-year follow-up visits.
PREDICTORS OF ADVERSE OUTCOMES. By multi-
variate analysis, both NOAF (hazard ratio [HR]: 1.96)
and pre-existing AF (HR: 1.55) were independent
predictors of increased mortality at 1 year. All signif-
icant predictors for 1-year mortality are reported in
Table 4. Independent predictors of stroke at 1 year
were a history of stroke (HR: 2.08) and the presence of
coronary artery disease. AF was not an independent
predictor of stroke, either at 30 days or 1 year, or of
death and stroke at 1 year (see the Online Appendix).
No signiﬁcant interaction was observed between
TAVR access site (transapical or transfemoral) and
pre-existing AF or NOAF in terms of all-cause death,
cardiac death, stroke, or the combination of all-cause
death and stroke.
PREDICTORS OF AF. Predictors of pre-existing AF
and NOAF were different. Independent predictors of
NOAF were age (HR: 1.07; p ¼ 0.0001), New York
Heart Association class III or IV (HR: 1.9; p ¼ 0.02),
nontransfemoral access route (HR: 2.9; p < 0.0001),
and balloon post-dilation of the prosthetic valve
(HR: 1.6; p ¼ 0.03). No interaction was observed be-
tween the degree of post-implantation paravalvular
leak and NOAF. Predictors of pre-existing AF were the
presence of moderate to severe mitral regurgitation
(HR: 1.42; 95% conﬁdence interval: 1.1 to 1.9;
p ¼ 0.01), moderate to severe tricuspid regurgitation
(HR: 2.33; 95% conﬁdence interval: 1.7 to 3.1;
p < 0.0001), and pulmonary hypertension (HR: 1.58;
95% conﬁdence interval: 1.23 to 2.2; p ¼ 0.0001).
DISCUSSION
The main ﬁndings of the present analysis in real-world
TAVR patients treated with balloon-expandable pros-
thetic valves and enrolled in the SOURCE XT registry
are as follows. First, AFwas a frequent ﬁnding, present
in more than 40% of patients. The prevalence rates of
pre-existing AF and NOAF were 35.6% and 7.2%,
respectively. Second, both pre-existing AF and NOAF
correlated with worse clinical outcomes compared
with sinus rhythm, including all-cause death, cardiac
death, and bleeding events. Third, only patients with
NOAF had a higher rate of stroke at long-term (2-year)
follow-up compared with the sinus rhythm group.
Last, predictors of NOAF were different from those of
pre-existing AF and included procedural variablessuch as nontransfemoral access route and balloon
post-dilation. Speciﬁcally, patients treated using
nontransfemoral approaches had a 3-fold greater risk
for NOAF compared with the transfemoral group.
AF is the most common sustained arrhythmia in
the general population and is characterized by an
increased prevalence and incidence worldwide (16).
TABLE 2 Procedural Characteristics According to the Presence of Pre-Existing or
New-Onset Atrial Fibrillation
Baseline AF
(n ¼ 685)
NOAF
(n ¼ 138)
Sinus Rhythm
(n ¼ 1,102) p Value
Implantation access route <0.0001
Transapical 271 (39.6%) 77 (55.8%) 300 (27.2%)
Transfemoral 395 (57.7%) 54 (39.1%) 760 (69.0%)
Subclavian 1 (0.1%) 0 (0.0%) 6 (0.5%)
Transaortic 18 (2.6%) 7 (5.1%) 36 (3.3%)
Bioprosthetic valve size (mm)
23 267 (39.3%) 52 (37.7%) 522 (47.5%) <0.0001
26 339 (49.9%) 59 (42.8%) 502 (45.7%)
29 74 (10.9%) 27 (19.6%) 75 (6.8%)
Percentage valve oversizing* 13.9  8.3 13.3  9.3 13.2  8.5 0.28
Type of anesthesia
General 492 (76.3%) 107 (84.9%) 712 (70.1%) 0.0003
Conscious sedation 153 (23.7%) 19 (15.1%) 303 (29.9%)
Total procedure time (min) 89.2  55.2 80.6  49.9 80.4  51.1 0.002
Volume of contrast used (ml) 129.3  96.1 125.3  92.0 124.1  100.2 0.55
Fluoroscopy time (min) 12.5  17.8 9.1  8.4 12.5  24.4 0.2
Pre-implantation BAV 654 (95.5%) 136 (99.3%) 1,070 (97.2%) 0.045
BAV balloon size (mm)
18 4 (0.7%) 0 (0.0%) 7 (0.7%) 0.75
20 353 (58.5%) 81 (62.8%) 604 (60.3%)
23 225 (37.3%) 41 (31.8%) 355 (35.4%)
25 21 (3.5%) 7 (5.4%) 36 (3.6%)
Number of balloon inﬂations for BAV
1 559 (88.6%) 124 (91.9%) 890 (85.7%) 0.18
$2 67 (10.6%) 11 (8.1%) 138 (13.3%)
Balloon dilations after valve deployment
None 512 (75.5%) 99 (71.7%) 903 (82.3%) 0.001
1 154 (22.7%) 36 (26.1%) 174 (15.9%)
2 12 (1.8%) 3 (2.2%) 20 (1.8%)
Technical success† 648 (94.6%) 136 (98.6%) 1,074 (97.5%) 0.003
Device success‡ 449 (82.7%) 97 (89.8%) 830 (87.7%) 0.01
Valve position
Correct at intended site 660 (96.5%) 136 (98.6%) 1,075 (97.5%) 0.26
Too high 9 (1.3%) 2 (1.4%) 10 (0.9%) 0.66
Too low 7 (1.0%) 0 (0.0%) 14 (1.3%) 0.89
Tilted 1 (0.1%) 0 (0.0%) 2 (0.2%) 0.98
Not implanted 8 (1.2%) 0 (0.0%) 3 (0.3%) 0.09
Procedure aborted
Before any device introduced 3 (0.4%) 0 (0.0%) 1 (0.1%) 0.39
Before BAV 0 (0.0%) 0 (0.0%) 1 (0.1%) 0.99
Conversion to conventional surgery 4 (0.6%) 0 (0.0%) 1 (0.1%) 0.24
Valve embolization 8 (1.2%) 0 (0.0%) 3 (0.3%) 0.09
Valve in valve (any) 13 (1.9%) 2 (1.4%) 20 (1.8%) 0.93
Planned 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.9
Due to complication 7 (1.0%) 2 (1.4%) 12 (1.1%) NA
Valve in other bioprosthesis 6 (0.9%) 0 (0.0%) 8 (0.7%) 0.94
Any complication during the procedure 105 (15.3%) 21 (15.3%) 127 (11.5%) 0.051
AV block 32 (4.7%) 9 (6.5%) 36 (3.3%) 0.1
Requiring temporary pacing 22 (3.2%) 4 (2.9%) 20 (1.8%) 0.16
Requiring permanent pacemaker 13 (1.9%) 4 (2.9%) 11 (1.0%) 0.11
Device malfunction 4 (0.6%) 0 (0.0%) 2 (0.2%) 1
Values are n (%) or mean  SD. *Percentage valve oversizing is deﬁned as: [(nominal valve diameter  annular
diameter)/annular diameter]  100. †An implantation procedure is considered technical success if the valve is
delivered to the intended site by 1 attempted procedure without procedure-related death within 48 h from im-
plantation.‡An implantationprocedure is considereddevice success if technical success is achievedand the subject is
free ofmoderate or severe aortic regurgitation and the subject has amean gradient less than 20mmHgat discharge.
BAV ¼ balloon aortic valvuloplasty; other abbreviations as in Table 1.
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942Aortic valve stenosis and AF share multiple common
risk factors, such as age and hypertension, and aortic
valve stenosis by itself is associated with a higher rate
of AF (5). Although AF has been shown to be a major
predictor of death, stroke, and congestive heart fail-
ure in patients treated or not by cardiac surgery, only
very few and small studies have assessed the epide-
miology and clinical impact of AF in TAVR-treated
patients (5–7,17). On the basis of previous reports,
the prevalence of pre-existing AF ranges from 22% up
to 41%, whereas the reported rate of NOAF after TAVR
varies widely from <1% to 32%, with higher rates
observed in the transapical TAVR series (6% to 38%)
compared with transfemoral ones (0% to 16%)
(3–5,18,19). The large differences among studies
might be explained by their heterogeneity in terms of
deﬁnitions and methods for AF detection, as well as
in terms of patient selection and TAVR approach (5).
In the pivotal PARTNER (Placement of Aortic Trans-
catheter Valves) trial, the rate of NOAF in cohort A
was 7.5% in patients treated with transfemoral access
and 11.5% in those treated with transapical access,
whereas in cohort B, the NOAF rate was as low as
0.7% (1,2). Similar inconsistencies can be observed
also in terms of the prognostic impact of AF in TAVR
patients. In 2 small series of patients undergoing
TAVR, Nuis et al. (10) and Amat-Santos et al. (8)
observed a signiﬁcant direct correlation between
NOAF and stroke only. Conversely, Yankelson et al.
(11) and Barbash et al. (9) found that pre-existing AF,
but not NOAF, increased the rate of mortality
and stroke at 1 year. Finally, Stortecky et al. (18) and
Nombela-Franco et al. (3) found that both NOAF and
pre-existing AF increased the risk for ischemic cardiac
and cerebrovascular events at follow-up.
Our study conﬁrms and extends these observations
to both total and cardiovascular mortality as well as to
bleeding events. Moreover, in our study patients with
AF had also a higher rate of rehospitalization for
recurrent congestive heart failure compared with
sinus rhythm.
Related to stroke, similarly to previous reports, we
found that the event rate was equally distributed
between early (<30 days) and late (>30 days)
follow-up, and trended higher in patients with NOAF
at long-term follow-up (8,20,21). Pre-existing AF and
NOAF were related to a numerically higher rate of
stroke but were not independent predictors of stroke
in this cohort. A signiﬁcantly higher stroke rate was
observed at 2-year follow-up only in the NOAF group
compared with the sinus rhythm group. This results
replicate those observed in the recent FRANCE-2
(French Transcatheter Aortic Valve Intervention
Registry) study for this speciﬁc endpoint (22). This
FIGURE 2 Event-Free Survival Curves of Study Groups (Sinus Rhythm, Pre-Existing Atrial Fibrillation, and New-Onset Atrial Fibrillation)
(A) Event-free survival curves for all-cause mortality according to the presence of any atrial ﬁbrillation (AF) (either pre-existing or new onset). (B) Event-free survival
curves for the combination of all-cause mortality and stroke according to the presence of any AF (either pre-existing or new onset). (C) Event-free survival curves
for all-cause mortality according to the presence of pre-existing AF or new-onset AF. (D) Event-free survival curves for the combination of all-cause mortality and stroke
according to the presence of pre-existing AF or new-onset AF.
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943might be related to the mixed pre-existing anti-
thrombotic regimen of patients treated with TAVR as
well as to a heterogeneous etiology of cerebral
ischemic events and their overall low rate. In con-
trast, the prominent impact of AF on cardiovascular
mortality without a comparable impact on stroke
appears to be more related to hemodynamic impair-
ment (i.e., recurrence of congestive heart failure) and
bleedings rather than to cerebrovascular events. In
this regard, patients with AF also had signiﬁcantly
higher rates of rehospitalization compared with the
sinus rhythm group. Granted, alternative treatment
strategies (e.g., left atrial appendage occlusion, non–
vitamin K–dependent anticoagulant agents) may play
a role in optimizing the risk/beneﬁt ratio in patients
not suitable for standard anticoagulation. The ongoingGALILEO (Global Study Comparing a Rivaroxaban-
Based Antithrombotic Strategy to an Antiplatelet-
Based Strategy After Transcatheter Aortic Valve
Replacement to Optimize Clinical Outcomes) ran-
domized trial comparing 2 antithrombotic strategies
following TAVR (aspirin plus rivaroxaban vs. aspirin
plus clopidogrel) will provide more data. Of note,
patients with pre-existing AF are excluded from this
study (23).
Related to bleeding events, the interaction be-
tween AF and bleedings in TAVR patients has been
mostly overlooked in the published research. In our
series, we found a signiﬁcant increase in bleeding
events in patients with AF compared with the sinus
rhythm group. Accordingly, a recent pooled analysis
from the PARTNER-1 trial and continued access
TABLE 3 1-Year Outcome Summary According to the Presence of Pre-Existing AF or NOAF
Outcome
Pre-Existing AF
(n ¼ 685)
NOAF
(n ¼ 138)
p Value, Pre-Existing
AF vs. NOAF
Sinus Rhythm
(n ¼ 1,102)
p Value, Pre-Existing
AF vs. Sinus Rhythm
p Value, NOAF vs.
Sinus Rhythm
All-cause death 178 (26.1%) 44 (32.1%) 0.22 92 (8.4%) <0.0001 <0.0001
Cardiac death 88 (13.8%) 21 (16.4%) 0.48 40 (3.8%) <0.0001 <0.0001
Stroke 42 (6.9%) 11 (8.6%) 0.42 56 (5.2%) 0.16 0.09
All vascular complications 120 (18.0%) 23 (17.0%) 0.78 172 (15.7%) 0.21 0.69
Major vascular complications 52 (7.7%) 8 (5.8%) 0.45 59 (5.4%) 0.04 0.76
Minor vascular complications 62 (9.2%) 14 (10.4%) 0.72 116 (10.6%) 0.36 0.91
Non-access-related vascular complication 8 (1.4%) 1 (0.7%) 0.64 3 (0.3%) <0.01 0.33
All bleeding events 163 (25.0%) 46 (34.2%) 0.02 212 (19.3%) 0.01 <0.0001
Major/life-threatening bleeding events 120 (18.2%) 28 (20.5%) 0.48 157 (14.3%) 0.03 0.051
Life-threatening bleeding events 46 (7.0%) 9, 10 (6.8%) 0.90 53 (4.8%) 0.05 0.35
Major bleeding events 86 (13.1%) 22 (16.1%) 0.30 117 (10.7%) 0.12 0.04
Minor bleeding events 59 (9.5%) 20 (15.7%) 0.03 70 (6.4%) 0.04 0.0003
Myocardial infarction 14 (2.5%) 2 (1.5%) 0.66 23 (2.2%) 0.77 0.73
Renal failure 157 (24.1%) 44 (32.5%) 0.03 155 (14.2%) <0.0001 <0.0001
Rehospitalization 225 (37.4%) 53 (44.0%) 0.16 254 (23.4%) <0.0001 <0.0001
Endocarditis 5 (0.9%) 2 (1.7%) 0.41 10 (1.0%) 0.9 0.41
New permanent pacemaker 85 (13.0%) 13 (9.7%) 0.30 66 (6.1%) <0.0001 0.08
Abbreviations as in Table 1.
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944registries populations by Généreux et al. (24) showed
that AF both at baseline and at 30 days nearly
doubled the risk for late major bleeding events after
TAVR ($30 days) (24). Furthermore, AF increased
1-year mortality in the same population, irrespective
of the occurrence major bleedings. These results from
North American pivotal studies are almost superim-
posable on our observations in a European real-world
cohort. Also, in our series, TAVR patients with NOAF
had more bleeding events compared with those with
pre-existing AF. Because AF is not known to increase
bleeding events by itself, we might hypothesize that
this association of AF with bleeding events reported
in both studies is inﬂuenced by the antithromboticTABLE 4 Predictors of Mortality at 1-Year Follow-Up by
Multivariate Logistic Regression
Signiﬁcant Predictor Hazard Ratio
95% Conﬁdence
Interval p Value
NOAF 1.96 (1.39–2.76) 0.0001
Baseline AF 1.55 (1.26–1.91) <0.0001
Renal failure 1.53 (1.25–1.86) <0.0001
Tricuspid regurgitation
(moderate to severe)
1.37 (1.09–1.73) 0.008
Coronary artery disease 1.29 (1.07–1.57) 0.008
NYHA functional class III/IV 1.28 (1.002–1.63) 0.01
COPD 1.28 (1.03–1.62) 0.03
BMI 0.96 (0.94–0.98) <0.0001
Logistic EuroSCORE 1.01 (1.004–1.01) 0.0012
Abbreviations as in Table 1.regimens used in these patients (25,26). To note, ev-
idence on the most appropriate post-procedural
antithrombotic regimen in terms of safety and efﬁ-
cacy in the setting of TAVR, especially when AF is
present, is currently lacking (25). According to the
SOURCE XT protocol, antithrombotic treatment of
patients was not recorded in the registry dataset.
Therefore, in this analysis it was not possible to
evaluate the relationship between antithrombotic
regimens and subsequent ischemic and bleeding
events, either globally or in the subset of patients
with AF. At the moment, antithrombotic treatment of
these patients is not supported by evidence coming
from any randomized study and is thus largely
translated in the TAVR setting from current pharma-
cological standards in patients undergoing percuta-
neous coronary interventions (25).
The association between nontransfemoral access
and NOAF has been already reported and has been
previously attributed to epicardial and pericardial
injury, similar to that occurring in cardiac surgery
(26). This ﬁnding, along with nonrandomized
outcome data of transfemoral versus nontransfemoral
access, represents additional evidence in favor of the
transfemoral route whenever feasible (5,27). The
gradual size reduction of new delivery systems and
transcatheter heart valves are allowing a progressive
shifting of TAVR procedures in this direction.
Balloon post-dilation was another independent
procedural predictor of NOAF observed in this study.
On the contrary, the ﬁnal presence of a paravalvular
PERSPECTIVES
WHAT IS KNOWN? Patients undergoing TAVR who have his-
tories of AF or who develop AF in the post-procedural period
have an increased risk for adverse events.
WHAT IS NEW? Procedural factors, such as the procedure ac-
cess route, may inﬂuence the chance to develop AF after TAVR.
The optimal antithrombotic regimen in TAVR patients, particu-
larly for those with AF (either pre-existing or new onset), is
unclear.
WHAT IS NEXT? Studies comparing different antithrombotic
therapies in such subsets of patients are needed. Also, more data
are needed to deﬁne the role of AF prevention and treatment in
TAVR patients.
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945leak was not associated with NOAF. This observation
might be explained by improvement of paravalvular
leak severity after balloon post-dilation, but the
association between post-deployment paravalvular
leak and NOAF deserves further investigation.
STUDY LIMITATIONS. We cannot exclude an under-
estimation of AF rate or some overlap between the
NOAF and pre-existing AF groups because of the
limited sensitivity of the methods used in clinical
practice to assess AF. Systematic 72-h continuous
post-TAVR electrocardiographic monitoring was not
routinely performed in this cohort. Additionally, no
information was available on the overall cohort to
differentiate paroxysmal from permanent AF at
baseline. Pre- and post-TAVR echocardiographic
evaluations were site reported and not reviewed by
an independent core laboratory. Finally, this study
was conducted in a population treated with TAVR
by means of balloon-expandable prosthetic valves
only. Generalizations of our results to patients
treated with other prosthesis types might be not
appropriate.
CONCLUSIONS
Presence of AF before and after TAVR was associated
with markedly increased risk for adverse events in
patients with aortic valve stenosis treated with
TAVR. We cannot exclude that our results were
inﬂuenced by the higher baseline risk of AF sub-
groups compared with those in sinus rhythm.
Notwithstanding, these results appear consistent with
those of the multicenter FRANCE-2 and PARTNER
studies, showing that AF had an independent detri-
mental effect on outcomes including cardiac death,bleeding, renal failure, and rehospitalization (22,24).
More data are needed to deﬁne the role of AF pre-
vention and treatment on outcomes in these patients.
Finally, the implementation of more comprehensive
TAVR risk scores, taking into account AF, remains a
relevant clinical need (28).
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